SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices rally on fears of Middle East supply disruptions, including escalating Iran tensions and risks to Gulf shipping and oil infrastructure. Traders are split between expecting the rally to continue and anticipating a sharp pullback if conflict fears ease or a deal emerges.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike rallied alongside cybersecurity peers despite a weaker broader market, with traders pointing to an Evercore ISI channel survey indicating firming security budgets and demand for identity and AI security. The move drew praise for the sectors relative strength, while skeptics questioned CRWDs high valuation.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

The PHP2Shell vulnerability has put cybersecurity stocks in focus, and traders see Cloudflares WAF protections as a potential beneficiary after the company deployed rules for customers. The community largely links NETs advance to that sector-wide security trade, though some are cautious about chasing the move.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Reports that Instacart is exploring a sale and has held preliminary talks with Uber have fueled speculation about a potential acquisition. Some traders see strategic value, while others worry another deal could add costs as the stock struggles; broader discussion also centers on robotaxi disruption fears.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Instacart is drawing attention after reports that it is exploring a potential sale and held preliminary takeover discussions with Uber and DoorDash. Traders are speculating about a bidding contest and takeover premium, while some question whether a deal is likely; no agreement has been confirmed.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

RARI is drawing attention amid a speculative bullish push centered on its low circulating supply, tiny market capitalization and thin liquidity, with traders arguing that renewed volume could magnify price moves. Skeptics counter that earlier gains faded and question the tokens prospects amid weak NFT interest, describing the action as a pump rather than a sustained recovery.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Traders are focused on Candels planned BLA submission for CAN-2409 in localized prostate cancer, supported by positive Phase 3 data, alongside upcoming updates from its lung and glioblastoma programs. Optimism about the regulatory milestone is tempered by the stocks sharp pullback and concerns about filing timing, cash needs and potential dilution, CEO share sales, and biotech-sector weakness.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks surged alongside cybersecurity peers after an Evercore ISI channel survey pointed to firming enterprise security budgets, with spending expected to favor identity and AI security. Traders also cited escalating vulnerability warnings as a demand tailwind, while some questioned the stocks high valuation.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

Lufaxs reverse stock split and preliminary Q3 loss warning are driving attention amid a sharp selloff, with traders also watching the forthcoming results for credit-quality and lending-volume clues. Bears see the warning as evidence of deeper business strain, while some holders argue tax-related charges inflate the headline loss and are focused on underlying operating trends.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

The sharp pullback is being linked by traders to broader aerospace-sector weakness, rising oil and jet-fuel concerns, and Safran comments suggesting softer widebody-market growth; some also point to geopolitical and macro volatility. The community is divided between viewing the decline as an overreaction with Rolls-Royces fundamentals intact and expecting further downside after the stocks run-up.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4 Biotech Stocks to Watch as Potential Takeover Targets

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’

Equity

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.


BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients. 


Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Investors need to pay close attention to BCRX stock based on the movements in the options market lately. 

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation

BioCryst raised its full-year 2026 total revenue outlook to $690 million to $715 million, up from its previous estimates of $635 million to $660 million.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Bullish Sentiment

<ul class="summary-bullets"><li>RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform,’ according to The Fly.</li><li>BioCryst expects revenue from Orladeyo between $625 million and $645 million in full-year 2026.</li><li>The brokerage sees longer-term potential from BioCryst’s second HAE drug, Navenibart.</li></ul>BioCryst Pharmaceuticals (BCRX) was in the spotlight on Thursday, after RBC Capital said the biotech firm faces a “challenging near-term outlook” after Pharvaris (PHVS) published strong late-stage data for hereditary angioedema (HAE) therapy.RBC downgraded BioCryst to ‘Sector Perform’ from ‘Outperform’ and lowered the price target to $11 from $13, according to The Fly. BCRX shares are currently trading near $8.The firm said Pharvaris’ experimental therapy could pressure its key hereditary angioedema drug, Orladeyo, and expects the shares to remain range-bound until new catalysts emerge.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/BCRX">BCRX shares</a> were down 8%, heading for their fifth straight session of losses.&nbsp;The stock has already shed more than 20% of its value so far over the five sessions.<h2 class="st-heading-2">Pharvaris Data Raises Competition</h2>The downgrade follows Phase 3 results for Pharvaris’ Deucrictibant XR, an experimental once-daily pill designed to prevent HAE attacks. HAE is a rare genetic condition that causes episodes of swelling in different parts of a child’s body, including the face, hands, and feet.Pharvaris said the drug reduced monthly attacks by 83% compared with placebo in its Chapter-3 study. The drug was generally well tolerated, and the company plans to begin seeking regulatory approvals in the first half of 2027.<h2 class="st-heading-2">RBC Expects Revenue Tailwinds For Orladeyo</h2>RBC believes the results could lead patients to switch away from Orladeyo and reduce the drug’s longer-term revenue to about $400 million to $450 million.The drug generated sales of over $600 million in full-year 2025, and the company expects revenue of $625 million to $645 million in 2026.Still, RBC sees longer-term potential from BioCryst’s second HAE drug, Navenibart. The Phase 3 study is fully enrolled, with six- and 12-month efficacy data expected in the third quarter of 2027.<h2 class="st-heading-2">Retail’s Take On BCRX</h2>Retail sentiment surrounding BCRX on Stocktwits remained ‘bullish’ over the past 24 hours, amid ‘high’ message volumes.One user opined that the “execution risk just rose for Navenibart.”<stembedurl>https://stocktwits.com/Cap_00/message/663973370</stembedurl>The stock has gained around 4% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/brent-futures-top-105-per-barrel-as-houthis-seize-strategic-red-sea-port-opec-cuts-2026-demand-outlook/cZtagdoRJ62">&nbsp;Brent Futures Top $105 Per Barrel As Houthis Seize Strategic Red Sea Port — OPEC Cuts 2026 Demand Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$7.65
Prev Close	$7.78
Open	$7.71
Dividend Yield	0.00%
50-Day Moving Average	$8.83
Beta	0.98
Avg. Volume	5.47M
PE Ratio	-5.17

52-Week High	$11.22
52-Week Low	$6.23
Market Capitalization	$1.99B
EPS (Annual)	$1.21
Price to Book	-4.37
Revenue Per Employee	$2.01M

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRX Fundamentals